Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The PERCY Quattro trial has been designed to evaluate the survival benefit of two cytokine
treatments, Interleukin-2 (IL2) and/or alpha interferon (IFN), for patients with intermediate
chance of response in metastatic renal cell carcinoma.
Eligible patients will be randomly assigned in a two-by-two factorial design to either
medroxyprogesterone (MPA), subcutaneous IFN, subcutaneous IL2, or a combination of IFN and
IL2.
The primary objective of the study is overall survival; secondary objectives are
progression-free survival, response rate, toxicity, and quality of life.
Phase:
Phase 3
Details
Lead Sponsor:
Centre Leon Berard
Collaborators:
French Immunotherapy Intergroup SCAPP (Sub-Cutaneous Administration Proleukin Program)